TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06174415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perceptual Learning
Description: Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
Study: NCT06091683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Description: Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy.
Study: NCT04784572

Intervention type: OTHER
Group type: OTHER
Intervention: first injection delay and second injection delay
Description: During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance.
Study: NCT05346068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPN™ NCB Super High Pressure PCI Balloon
Description: In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave™ C2 IVL Catheter
Description: In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion.
Study: NCT05228314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2020S
Description: a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2020S
Description: a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2020S
Description: a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squalene based adjuvant
Description: Squalene based adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squalene based adjuvant
Description: Squalene based adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squalene based adjuvant
Description: Squalene based adjuvant
Study: NCT06057467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Agents
Description: Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Agents
Description: Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
Study: NCT05986396

Intervention type: DEVICE
Intervention: INSPIRIS Resilia (model 11500A)
Description: Aortic Valve
Study: NCT04919798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bladder emptying device
Description: The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bladder emptying device
Description: The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
Study: NCT05940090

Intervention type: DEVICE
Intervention: SkinIO
Description: The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
Study: NCT05243732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Music Listening
Description: Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given
Study: NCT05959356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Envafolimab + mFOLFOXIRI
Description: Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + mFOLFOX6/FOLFIRI
Description: Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Study: NCT05741619

Intervention type: OTHER
Intervention: Long-term outcome
Description: Autonomy, physical examination, behavioural disorders
Study: NCT05083286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Injection of glabellar rhytids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Injection of glabellar rhytids
Study: NCT06072456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic lateral suspension
Description: Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic pectopexy
Description: Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Description: Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
Study: NCT06518018

Intervention type: RADIATION
Intervention: HDR brachytherapy (30Gy single fraction)
Description: Study Group receives a novel triple combination therapy for advanced NSCLC in the second-line setting. The treatment begins with a single fraction of high-dose rate (HDR) brachytherapy, delivering 30 Gy locally to the tumor site. This is followed within 1-3 days by systemic therapy, combining immunotherapy and chemotherapy , both administered intravenously.

Intervention type: DRUG
Intervention: Immunotherapy
Description: Control Group receives the current standard of care for second-line treatment of advanced NSCLC. This regimen consists of a combination of immunotherapy and chemotherapy , both administered intravenously
Study: NCT06176911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: 200 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: 200 mg twice daily.
Study: NCT05275504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01488
Description: TT-01488 tablet will be administered orally once daily per protocol defined schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01488
Description: TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Study: NCT05228314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squalene based adjuvant
Description: Squalene based adjuvant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CpG/alum adjuvant
Description: CpG/alum adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CpG/alum adjuvant
Description: CpG/alum adjuvant
Study: NCT06042062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spacer
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spacer
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
Study: NCT05846737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.
Study: NCT04772560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1 for Astigmatism
Description: Daily disposable soft toric contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1 for Astigmatism
Description: Daily disposable soft toric contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1 Sphere
Description: Daily disposable soft spherical contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1 Sphere
Description: Daily disposable soft spherical contact lens
Study: NCT04910841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM GUARDIAN 2
Description: continuous blood glucose monitoring system
Study: NCT05968729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 0.25 m/s asymmetric session first
Description: Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 0.50 m/s asymmetric session first
Description: Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s.
Study: NCT05205889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile intervention on values and goals in patients with chronic pain.
Description: The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
Study: NCT04711226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 IV infusion
Study: NCT04970225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 blood sample
Description: 4 tubes of 7 ml per sample (a single sample)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 blood samples
Description: 4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 blood samples
Description: 4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
Study: NCT05675488

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Thickness of flexor tendon and A1 pulley at MCP joint level

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Thickness of flexor tendon and A1 pulley at MCP joint level
Study: NCT06112886

Intervention type: OTHER
Intervention: There was no intervention in this study
Description: There was no intervention in this study
Study: NCT05179590

Intervention type: OTHER
Intervention: Quality of Dream
Description: Patients frequently report having dreams during general anesthesia, and the dreams are often reported to be pleasant dreams.~However, factors associated with the quality of dreams during general anesthesia have not been clarifed. The aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.~This prospective observational study included patients scheduled for elective surgery under general anesthesia.
Study: NCT05785442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra Prefilled Syringe
Description: Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
Study: NCT05216354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
Study: NCT06208371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection and/or ablation therapy and/or SBRT
Description: Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Chemotherapy
Description: Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
Study: NCT05438472

Intervention type: OTHER
Intervention: data collection in healthcare professionals with COVID-19 mRNA vaccine booster
Description: Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT \> 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
Study: NCT05291715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)
Description: Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)
Study: NCT05933850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Families Programme Intervention
Description: This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strong Families Programme Intervention
Description: This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
Study: NCT05274893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2011 and Abraxane®
Description: IV infusion, 260 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2011 and Abraxane®
Description: IV infusion, 260 mg/m\^2
Study: NCT05868434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.
Description: Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
Study: NCT06521762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: 2 mg/day oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be given in conjunction with study drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids will be given in conjunction with study drug or placebo